RT Journal Article
T1 Validation of diagnostic nomograms based on CE-MS urinary biomarkers to detect clinically significant prostate cancer.
A1 Frantzi, Maria
A1 Heidegger, Isabel
A1 Roesch, Marie C
A1 Gomez-Gomez, Enrique
A1 Steiner, Eberhard
A1 Vlahou, Antonia
A1 Mullen, William
A1 Guler, Ipek
A1 Merseburger, Axel S
A1 Mischak, Harald
A1 Culig, Zoran
K1 Capillary electrophoresis
K1 Non-invasive urine biomarker
K1 Prostate cancer aggressivity
K1 Urinary peptide marker
AB Prostate cancer (PCa) is one of the most common cancers and one of the leading causes of death worldwide. Thus, one major issue in PCa research is to accurately distinguish between indolent and clinically significant (csPCa) to reduce overdiagnosis and overtreatment. In this study, we aim to validate the usefulness of diagnostic nomograms (DN) to detect csPCa, based on previously published urinary biomarkers. Capillary electrophoresis/mass spectrometry was employed to validate a previously published biomarker model based on 19 urinary peptides specific for csPCa. Added value of the 19-biomarker (BM) model was assessed in diagnostic nomograms including prostate-specific antigen (PSA), PSA density and the risk calculator from the European Randomized Study of Screening. For this purpose, urine samples from 147 PCa patients were collected prior to prostate biopsy and before performing digital rectal examination (DRE). The 19-BM score was estimated via a support vector machine-based software based on the pre-defined cutoff criterion of - 0.07. DNs were subsequently developed to assess added value of integrative diagnostics. Independent validation of the 19-BM resulted in an 87% sensitivity and 65% specificity, with an AUC of 0.81, outperforming PSA (AUC PSA: 0.64), PSA density (AUC PSAD: 0.64) and ERSPC-3/4 risk calculator (0.67). Integration of 19-BM with the rest clinical variables into distinct DN, resulted in improved (AUC range: 0.82-0.88) but not significantly better performances over 19-BM alone. 19-BM alone or upon integration with clinical variables into DN, might be useful for detecting csPCa by decreasing the number of biopsies.
PB Springer
YR 2022
FD 2022-06-09
LK http://hdl.handle.net/10668/19808
UL http://hdl.handle.net/10668/19808
LA en
NO Frantzi M, Heidegger I, Roesch MC, Gomez-Gomez E, Steiner E, Vlahou A, Mullen W, et al. Validation of diagnostic nomograms based on CE-MS urinary biomarkers to detect clinically significant prostate cancer. World J Urol. 2022 Sep;40(9):2195-2203
NO This work was supported by the BioGuidePCa (E! 11023, Eurostars) funded by BMBF (Germany) and FFG (Austria).
DS RISalud
RD Apr 5, 2025